MNMD - Mind Medicine (MindMed) Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$20.00
DETAILS
HIGH:
$28.00
LOW:
$14.00
MEDIAN:
$20.00
CONSENSUS:
$20.00
DOWNSIDE:
3.33%
About Mind Medicine (MindMed) Inc. (https://www.mindmed.co)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Robert Barrow | Chief Executive Officer & Director | 1989 | $997,010 USD |
| Daniel Rollings Karlin | Chief Medical Officer | 1980 | $703,319 USD |
| Mark R. Sullivan | Chief Legal Officer & Corporate Secretary | 1971 | $638,607 USD |
| Brandi L. Roberts | Chief Financial Officer | 1974 | $608,624 USD |
| Scott Freeman | Co-Founder & Clinical Advisor | 1957 | $309,621 USD |
| Beth Calitri | Vice President of Corporate Communications | – | – |
| Gregg Pratt | Chief Regulatory & Quality Assurance Officer | – | – |
| Leonard Latchman | Co-founder | – | – |
| Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | – | – |
| Stephanie Fagan | Chief Corporate Affairs Officer | – | – |